MindMed announces issuance of new patent for MM120 ODT

Mind Medicine announced the issuance of a new patent by the United States Patent and Trademark Office USPTO covering MM120 or lysergide. MM120 is currently in clinical development for adults with generalized anxiety disorder GAD and presents opportunities for treating a range of additional brain health disorders. The newly issued patent includes claims covering the pharmaceutical formulation, methods of manufacturing and method of treatment for MM120 ODT, MindMed’s proprietary and pharmaceutically optimized form of lysergide or LSD . The pharmaceutical formulation patent is the first US patent issued on the MM120 ODT formulation and extends the Company’s intellectual property protection for MM120 through 2041…”We have adopted an effective, multi-pronged strategy to protect MM120 and its potential uses across a number of large therapeutic indications like GAD and other brain health disorders,” said Rob Barrow, Chief Executive Officer of MindMed. “The issuance of this patent extends our IP protection for MM120 to at least 2041 and, more importantly, covers the unique properties of our MM120 ODT formulation. These clinical features underscore our dedication to creating treatments that are effective and optimize the patient’s experience. Our PK bridging study reported earlier this year demonstrated these advantageous properties and support this formulation’s use in our Phase 3 clinical trials, and, if ultimately approved, for clinical use.”